Telix
Manufacturing · Australia · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
55 Flemington Rd L 4, North Melbourne, V...Phone Number
+61 330933897Website
www.telixpharma.comRevenue
$558.5 MillionStock Symbol
TLXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Telix
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as theranostics, which use molecularly targeted radiation to both image and treat cancer. Telix's pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its lead commercial product, Illuccix, is an approved PSMA-PET/CT imaging agent for prostate cancer with regulatory clearance from the FDA, Australia's TGA, and Health Canada.Explore more
Telix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Telix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Telix has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Telix
Earning: See what the market has to say on Telix recently announced quarterly report
Telix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Telix had a recent Job posting/layoffs
Check out if Telix is spiking on competitors!
Funding: Get notified immidiatlly once Telix has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Telix launches new products
Recommended Actions
Reach out to Masked Content who joined Telix as Masked Content
Find 3 more new buyers
Compare Similar Companies to Telix
Compare insights from companies similar to Telix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Telix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Telix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Telix.
Telix financials insights
Gather financial insights about Telix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Corporate Investment
$25M
2024
Share Placement
$434M
Share Placement
$434M
Telix Tech Stack
A closer look at the technologies used by Telix
Most Recent Scoops
Hiring Plans
Telix has more open roles in Human Resources than it has had at any time in the past 12 months. Technologies mentioned include: Remote. Areas of expertise include: HRIS Administration, Payroll Administration, and Human Resources Concepts.
Hiring Plans
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Telix News & Media
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
MELBOURNE, Australia and INDIANAPOLIS , July 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), Telix’s first-in-class prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate (rADC) therapy candidate. The study’s scientific purpose was to evTelix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] Group revenue of US$247 million, up 7% quarter-over-quarter (QoQ) and up 21% year-over-year (YoY). Precision Medicine continues to deliver strong growth, revenue of US$202 million, up 9% QoQ and up 30% YoY. Telix expects FY 2026Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first radiopharmaceutical therapy to enter Phase 3 development for ccRCC. LUTEON is a randomized, prospective, open label, multi-center study evaluating a CAIX-targeting radionuclide therapy in patients with relapsed or reTelix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
• First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). • LUTEON is the first Phase 3 study of a CAIX[2]-targeted radiopharmaceutical therapy in ccRCC MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Telix
Sign Up For FreeTo access detailed company insights
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as... Read More
